Cue Health Inc. (HLTH) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.09: the stock has moved about 9% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCue Health Inc. (HLTH) trades at $27.79. Cue Health Inc. develops and commercializes diagnostic platforms for various healthcare needs. The company's integrated care platform aims to provide rapid and accurate diagnostic information to individuals, enterprises, and healthcare providers. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026HLTH stock analysis for 2026: The stored analyst price target for Cue Health Inc. is $0.50; its date is unknown, so no upside or downside is derived from it against the current price of $27.79. Key factors: analyst coverage, company fundamentals.
Cue Health Inc. (HLTH) Healthcare & Pipeline Overview
Cue Health Inc. is a healthcare technology company focused on developing and marketing its Cue Integrated Care platform, which offers rapid, point-of-care diagnostic testing solutions. The platform targets individuals, enterprises, healthcare providers, and public health agencies, positioning it within the evolving landscape of decentralized diagnostics.
What Is the Investment Thesis for HLTH?
Cue Health Inc. presents a high-risk, high-reward investment opportunity within the point-of-care diagnostics market. The company's Cue Integrated Care platform offers a potentially disruptive solution for rapid and accurate testing. However, with a market capitalization of $0.01 billion, a negative profit margin of -581.5%, and a negative gross margin of -97.9%, the company faces significant financial challenges. Future growth hinges on expanding the test menu beyond COVID-19, securing regulatory approvals for new tests, and achieving wider market adoption. The company's beta of 1.09 suggests its stock price is as volatile as the market. Investors should carefully consider the company's financial position, competitive landscape, and execution risks before investing. The company's success depends on its ability to innovate, commercialize new diagnostic tests, and achieve profitability.
Based on FMP financials and quantitative analysis
HLTH Key Highlights
Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative profit margin of -581.5% reflects substantial losses and the need for improved cost management and revenue generation.
- Negative gross margin of -97.9% suggests that the cost of goods sold exceeds revenue, indicating unsustainable pricing or high production costs.
- Beta of 1.09 indicates that the stock is slightly more volatile than the overall market.
- The company operates in the rapidly evolving point-of-care diagnostics market, driven by demand for faster and more convenient testing solutions.
Who Are HLTH's Competitors?
HLTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ETAO ETAO International Co., Ltd. | $1.91 | -31.79% | $9.78M | — |
| FRTX Fresh Tracks Therapeutics, Inc. | $0.94 | -0.53% | $5.59M | — |
| KA Kineta, Inc. | $0.57 | -30.77% | $7.05M | — |
| LCI Lannett Company, Inc. | $0.69 | 0.00% | $7.38M | — |
| VEEV Veeva Systems Inc. | $318.18 | -1.50% | $52.3B | 93 5-pillar |
| GEHC GE HealthCare Technologies Inc. | $71.98 | +0.74% | $32.5B | 63 5-pillar |
| TEM Tempus AI, Inc. | $67.16 | -0.67% | $11.8B | 33 5-pillar |
| BTSG BrightSpring Health Services, Inc. | $58.88 | -2.05% | $11.7B | 81 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLTH's Key Strengths?
Integrated platform with hardware and software components.
- Rapid and accurate diagnostic results at the point of care.
- Data and analytics capabilities for healthcare providers and patients.
- Existing COVID-19 testing kits provide a foundation for future growth.
What Are HLTH's Weaknesses?
Negative profit and gross margins indicate financial instability.
- Limited test menu beyond COVID-19.
- Dependence on regulatory approvals for new tests.
- Intense competition in the point-of-care diagnostics market.
What Are the Key Risks for HLTH?
Regulatory hurdles and delays in obtaining approvals for new tests.
- Intense competition from established players in the diagnostics market.
- Financial instability due to negative profit and gross margins.
- Changes in healthcare policies and reimbursement rates affecting the adoption of point-of-care diagnostics.
What Are HLTH's Competitive Advantages?
- Proprietary Technology: The Cue Integrated Care platform is based on proprietary technology, providing a competitive advantage.
- Integrated System: The integrated hardware and software components of the Cue platform create a seamless user experience.
- Rapid and Accurate Results: The Cue platform delivers rapid and accurate diagnostic results at the point of care.
- Data and Analytics Capabilities: The Cue Data and Innovation Layer provides valuable insights for healthcare providers and patients.
What Does HLTH Do?
Cue Health Inc., established in 2010 and headquartered in San Diego, California, is a healthcare technology company dedicated to designing and developing a diagnostic platform for a range of diagnostic tests. The company's core offering is the Cue Integrated Care platform, a comprehensive system comprising both hardware and software components. This platform includes the Cue Health Monitoring System, which features the Cue Reader (a portable, reusable reader), the Cue Cartridge (a single-use test cartridge), and the Cue Wand (a sample collection wand). The Cue Data and Innovation Layer provides cloud-based data and analytics capabilities, while Cue Virtual Care Delivery Apps, including the Cue Health App and Cue Enterprise Dashboard, facilitate virtual care delivery. The company also offers Cue Ecosystem Integrations and Apps, enabling integration with third-party applications and sensors. Initially, Cue Health gained prominence through its COVID-19 testing kits designed for use with the Cue Health Monitoring System. These kits provided rapid, on-site testing capabilities, addressing a critical need during the pandemic. The company's focus extends beyond COVID-19, with plans to expand its platform to detect a variety of other infectious diseases and health conditions. Prior to December 2017, the company was known as Cue Inc.
What Products and Services Does HLTH Offer?
- Designs and develops a diagnostic platform for various diagnostic tests.
- Offers the Cue Integrated Care platform, comprising hardware and software components.
- Provides the Cue Health Monitoring System, including the Cue Reader, Cue Cartridge, and Cue Wand.
- Offers the Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability.
- Provides Cue Virtual Care Delivery Apps, including Cue Health App and Cue Enterprise Dashboard.
- Offers Cue Ecosystem Integrations and Apps, allowing integrations with third-party applications and sensors.
- Provides COVID-19 testing kits for the Cue Health Monitoring System.
How Does HLTH Make Money?
- Sells the Cue Health Monitoring System, including the Cue Reader and Cue Cartridges.
- Generates revenue from the sale of COVID-19 testing kits.
- Offers data and analytics services through the Cue Data and Innovation Layer.
- Provides virtual care delivery applications through the Cue Health App and Cue Enterprise Dashboard.
What Industry Does HLTH Operate In?
Cue Health Inc. operates within the medical and healthcare information services industry, a sector experiencing rapid growth due to technological advancements and increasing demand for point-of-care diagnostics. The market is characterized by intense competition, with established players like Laboratory Corporation of America (LCI) and emerging companies vying for market share. The industry is driven by trends such as personalized medicine, remote patient monitoring, and the need for rapid and accurate diagnostic testing. Cue Health's success depends on its ability to differentiate its platform, secure regulatory approvals, and establish strategic partnerships within this competitive landscape.
Who Are HLTH's Key Customers?
- Individuals seeking convenient and accessible diagnostic testing.
- Enterprises looking to provide on-site testing for employees.
- Healthcare providers needing rapid and accurate diagnostic information.
- Payors seeking to improve patient outcomes and reduce healthcare costs.
- Public health agencies requiring rapid disease surveillance and response capabilities.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● Covered by analysts
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 56 snapshots
| 2026-08-23 | 44 |
| 2026-09-03 | 44 |
| 2026-09-14 | 44 |
| 2026-09-25 | 44 |
| 2026-10-09 | 44 |
| 2026-10-26 | 44 |
What changed?
The score has stayed at 44.
Over the same 31 days the stock moved -6.5%.
Forward Outlook
Wall Street analysts project Cue Health Inc. revenue of about $162.4M for fiscal 2026, with EPS near $-0.31.
Insider Activity
12 transactions · 0 purchases, 3 sales, 9 other transactions · 7 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
HLTH Financials
Bull Case vs Bear Case
Bull Case
- Integrated platform with hardware and software components.
- Rapid and accurate diagnostic results at the point of care.
- Data and analytics capabilities for healthcare providers and patients.
- Existing COVID-19 testing kits provide a foundation for future growth.
Bear Case
- Negative profit and gross margins indicate financial instability.
- Limited test menu beyond COVID-19.
- Dependence on regulatory approvals for new tests.
- Intense competition in the point-of-care diagnostics market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HLTH Latest News
-
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
benzinga · Sep 22, 2026
HLTH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HLTH.
Price Targets
Consensus target: $0.50
HLTH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HLTH; grades run from A+ (80-100) to F (below 30).
Leadership: Clint Sever
CEO
Clint Sever serves as the CEO of Cue Health Inc. His background includes experience in technology and healthcare, with a focus on developing and commercializing innovative diagnostic solutions. He has been instrumental in guiding Cue Health through its growth phase, including the development and launch of the Cue Integrated Care platform. His expertise spans product development, regulatory affairs, and market strategy.
Track Record: Under Clint Sever's leadership, Cue Health has secured FDA authorization for its COVID-19 test and expanded its platform to address other diagnostic needs. He has overseen the company's growth in revenue and market presence, as well as its efforts to establish strategic partnerships with healthcare providers and payers. Key milestones include the commercialization of the Cue Health Monitoring System and the development of the Cue Data and Innovation Layer.
Common Questions About HLTH (Healthcare)
What does Cue Health Inc. do?
Cue Health Inc. is a healthcare technology company focused on developing and commercializing its Cue Integrated Care platform. This platform provides rapid, point-of-care diagnostic testing solutions for individuals, enterprises, healthcare providers, and public health agencies. The Cue platform consists of a portable reader, single-use test cartridges, and a cloud-based data and analytics system.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- The analysis is based on publicly available information and management commentary.
- Future performance is subject to various risks and uncertainties.